New trial hunts down lingering melanoma DNA to stop cancer return
NCT ID NCT06319196
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for people with high-risk melanoma who have tiny bits of tumor DNA still in their blood after surgery. It compares a two-drug immunotherapy combo against a single drug to see which better clears these hidden cancer cells. About 54 participants will be randomly assigned to one of the two treatments and monitored for a year.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UHN- Princess Margaret Cancer Center
RECRUITINGToronto, Ontario, M5G 1Z5, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- E-Learning could sharpen Doctors' eye for skin cancer
- Can a new drug tame advanced solid tumors?
- Can a short Pre-Surgery immunotherapy course replace Long-Term adjuvant treatment for melanoma?
- Can an immune checkpoint blocker outperform interferon in keeping mucosal melanoma at bay?
- Can a single tracer light up cancer's first stop? a trial puts a hybrid dye-and-radioactive marker to the test.
- Could a Two-Drug combo reawaken the immune system against resistant cancers?